Scinai Immunotherapeutics Q2 2024 Financial Results and Business Update FAQ
Summary
What is Scinai Immunotherapeutics’ focus?
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit.
What were the recent highlights from Scinai’s Q2 2024 report?
Recent highlights include the restructuring of a $29 million bank loan to equity, plans to regain Nasdaq compliance by August 23, 2024, and receiving approximately $600,000 in CDMO work orders since January 2024.
When is Scinai’s webinar to discuss Q2 2024 results?
Scinai plans to host a webinar on August 20, 2024, at 11 a.m. EDT/6 p.m. Israel Time to discuss its Q2 2024 results and business update.
What is the status of Scinai’s NanoAb development?
Scinai is aggressively advancing the NanoAb preclinical development, with a Phase 1/2a clinical trial of its anti-IL-17A/F NanoAb (SCN-1) in Plaque Psoriasis anticipated to commence in the second half of 2025.
How did Scinai’s financial performance in H1 2024 compare to H1 2023?
R&D expenses decreased to $2,788,000 in H1 2024 from $3,449,000 in H1 2023, and net loss reduced to $4,481,000 in H1 2024 from $7,277,000 in H1 2023.
What are Scinai’s revenue expectations from its CDMO business?
Scinai maintains confidence in its guidance for 2024 of $1.25 million in expected sales revenues from its CDMO business and anticipates revenues to increase materially in the coming years.
Where can I find more information about Scinai Immunotherapeutics?
For more information, visit the company’s website at www.Scinai.com or the latest news and updates relating to SCNI in the company’s newsroom at https://ibn.fm/SCNI.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 132797